Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

References

• Martin TG, Shah N, Richter J, et al. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021;127(11):1816–1826.
   PubMed Web of Science ®Google Scholar
• Muller LME, Migneco G, Scott GB, et al. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. J Immunother Cancer. 2021;9(3):e001803.
   Web of Science ®Google Scholar
• Mireles-Cano JN, Escoto-Venegas E, García-González OG, et al. A management algorithm for vertebral destruction syndrome by multiple myeloma and metastatic spinal cord compression. Acta Ortop Mex. 2020;34(5):293–297.
   PubMedGoogle Scholar
• Belgioia L, Vagge S, Tagliafico A, et al. How can imaging help the radiation oncologist in multiple myeloma treatment. Medicina (Kaunas). 2020;57(1):20.
   PubMed Web of Science ®Google Scholar
• Kim Y, Seo D, Kim WJC. Types of cancer and outcomes in patients with cancer requiring admission from the emergency department: a nationwide. population-based study. 2016-2017. Cancer. 2021;127(14):2553–2561.
   PubMed Web of Science ®Google Scholar
• Zingoni A, Vulpis E, Cecere F, et al. MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma. Front Immunol. 2018;9:926.
   PubMed Web of Science ®Google Scholar
• Couto Oliveira A, Ribeiro IP, Pires LM, et al. Genomic characterisation of multiple myeloma: study of a Portuguese cohort. J Clin Pathol. 2021. doi:10.1136/jclinpath-2020-207204
   PubMed Web of Science ®Google Scholar
• Mian HS, Fiala MA, Sanchez L, et al. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”. Ann Hematol. 2021;100(5):1261–1266.
   PubMed Web of Science ®Google Scholar
• Wu P, Fang X, Liu Y, et al. N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway. Cell Death Dis. 2021;12(4):298.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Liu L, et al. Circular RNAs: new biomarkers of chemoresistance in cancer. Cancer Biol Med. 2021;18(2):421–436.
   PubMed Web of Science ®Google Scholar
• Tang X, Ren H, Guo M, et al. Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J. 2021;19:910–928.
   PubMed Web of Science ®Google Scholar
• Zhai X, Zhang Y, Xin S, et al. Insights into the involvement of circular RNAs in autoimmune diseases. Front Immunol. 2021;12:622316.
   PubMed Web of Science ®Google Scholar
• Xia Y, Lv J, Jiang T, et al. CircFAM73A promotes the cancer stem cell-like properties of gastric cancer through the miR-490-3p/HMGA2 positive feedback loop and HNRNPK-mediated β-catenin stabilization. J Exp Clin Cancer Res. 2021;40(1):103.
   PubMed Web of Science ®Google Scholar
• Liu R, Li Y, Wu A, et al. Identification of plasma hsa_circ_0005397 and combined with serum AFP, AFP-L3 as potential biomarkers for hepatocellular carcinoma. Front Pharmacol. 2021;12:639963.
   PubMed Web of Science ®Google Scholar
• Yu S, Ai L, Wei W, et al. circRNA circ-MYBL2 is a novel tumor suppressor and potential biomarker in multiple myeloma. Hum Cell. 2021;34(1):219–228.
   PubMed Web of Science ®Google Scholar
• Liu F, Wang YL, Wei JM, et al. Upregulation of circ_0000142 promotes multiple myeloma progression by adsorbing miR-610 and upregulating AKT3 expression. J Biochem. 2021;169(3):327–336.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang X, Fu S, et al. Circular RNA circ-CDYL sponges miR-1180 to elevate yes-associated protein in multiple myeloma. Exp Biol Med (Maywood). 2020;245(11):925–932.
   PubMed Web of Science ®Google Scholar
• Liu X, Tang H, Liu J, et al. hsa_circRNA_101237: a novel diagnostic and prognostic biomarker and potential therapeutic target for multiple myeloma. Cancer Manag Res. 2020;12:2109–2118.
   PubMed Web of Science ®Google Scholar
• Lin H, Zeng L, Yang J, et al. A machine learning-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Front Oncol. 2021;11:608260.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Q, Lu Y, et al. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep. 2021;11(1):6069.
   PubMed Web of Science ®Google Scholar
• Lu C, Rong D, Hui B, et al. CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma. Cell Death Discov. 2021;7(1):321.
   PubMed Web of Science ®Google Scholar
• Jia H, Liu Y, Lv S, et al. LBX2-AS1 as a novel diagnostic biomarker and therapeutic target facilitates multiple myeloma progression by enhancing mRNA stability of LBX2. Front Mol Biosci. 2021;8:706570.
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang D, Zhou N, et al. Circular RNA protein tyrosine kinase 2 promotes cell proliferation, migration and suppresses apoptosis via activating microRNA-638 mediated MEK/ERK, WNT/β-catenin signaling pathways in multiple myeloma. Front Oncol. 2021;11:648189.
   PubMed Web of Science ®Google Scholar
• Wang W, Lin Y, Zhang G, et al. Circ_0002346 suppresses non-small-cell lung cancer progression depending on the regulation of the miR-582-3p/STXBP6 axis. Int J Genomics. 2021;2021:1–20.
   Web of Science ®Google Scholar
• Mahaweni NM, Ehlers FAI, Bos GMJ, et al. Tuning natural killer cell anti-multiple myeloma reactivity by targeting inhibitory signaling KIR and NKG2A. Front Immunol. 2018;9:2848.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Morè S, et al. Novel experimental drugs for treatment of multiple myeloma. J Exp Pharmacol. 2021;13:245–264.
   PubMedGoogle Scholar
• Zhang M, Zhu Z, Xia Z, et al. Comprehensive circRNA-microRNA-mRNA network analysis revealed the novel regulatory mechanism of Trichosporon asahii infection. Mil Med Res. 2021;8(1):19.
   PubMed Web of Science ®Google Scholar
• Shen P, Yang T, Chen Q, et al. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Mol Cancer. 2021;20(1):51.
   PubMed Web of Science ®Google Scholar
• Huang Q, Sun Y, Huang Q, et al. Association between circular RNAs and intracranial aneurysm rupture under the synergistic effect of individual environmental factors. Front Neurol. 2021;12:594835.
   PubMed Web of Science ®Google Scholar
• Shi L, Zhang H, Sun J, et al. CircSEC24A promotes IL-1β-induced apoptosis and inflammation in chondrocytes by regulating miR-142-5p/SOX5 axis. Biotechnol Appl Biochem. 2021. DOI:10.1002/bab.2145
   Web of Science ®Google Scholar
• Bi L, Zhang C, Yao Y, et al. Circ-HIPK3 regulates YAP1 expression by sponging miR-381-3p to promote oral squamous cell carcinoma development. J Biosci. 2021;46(1):20.
   PubMed Web of Science ®Google Scholar
• Rice M, Naeger S, Singh EJO, et al. Real-world treatment patterns and outcomes among multiple myeloma patients with asthma and COPD in the United States. Oncol Ther. 2021;9(1):195–212.
   PubMed Web of Science ®Google Scholar
• Huang W, Qian T, Huang Z, et al. Increased expression of IFI16 predicts adverse prognosis in multiple myeloma. Pharmacogenomics J. 2021;21(4):520–532.
   PubMed Web of Science ®Google Scholar